The C-terminal region of human NFATc2 binds cJun to synergistically activate interleukin-2 transcription
At eukaryotic promoters, multi-faceted protein–protein and protein–DNA interactions can result in synergistic transcriptional activation. NFAT and AP-1 proteins induce interleukin-2 (IL-2) transcription in stimulated T cells, but the contributions of individual members of these activator families to...
Saved in:
Published in | Molecular immunology Vol. 47; no. 14; pp. 2314 - 2322 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Elsevier Ltd
01.08.2010
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | At eukaryotic promoters, multi-faceted protein–protein and protein–DNA interactions can result in synergistic transcriptional activation. NFAT and AP-1 proteins induce interleukin-2 (IL-2) transcription in stimulated T cells, but the contributions of individual members of these activator families to synergistically activating IL-2 transcription is not known. To investigate the combinatorial regulation of IL-2 transcription we tested the ability of different combinations of NFATc2, NFATc1, cJun, and cFos to synergistically activate transcription from the IL-2 promoter. We found that NFATc2 and cJun are exclusive in their ability to synergistically activate human IL-2 transcription. Protein–protein interaction assays revealed that in the absence of DNA, NFATc2, but not NFATc1, bound directly to cJun/cJun dimers, but not to cFos/cJun heterodimers. A region of NFATc2 C-terminal of the DNA binding domain was necessary and sufficient for interaction with cJun in the absence of DNA, and this same region of NFATc2 was required for the synergistic activation of IL-2 transcription in T cells. Moreover, expression of this C-terminal region of NFATc2 specifically repressed the synergistic activation of IL-2 transcription. These studies show that a previously unidentified interaction between human NFATc2 and cJun is necessary for synergistic activation of IL-2 transcription in T cells. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 Present address: Hertie Institute for Clinical Brain Research, University of Tuebingen, D-72076 Tuebingen, Germany Present address: CeloNova BioSciences, Inc., Peachtree City, GA 30269 Present address: Brisbane, CA 94005 |
ISSN: | 0161-5890 1872-9142 |
DOI: | 10.1016/j.molimm.2010.05.287 |